Filing identity and reporting period
Important identification mismatch: The supplied filing is for Trail One, Inc., a Nevada development-stage company, not Citius Pharmaceuticals, Inc. The filing reports the quarter and six months ended March 31, 2012, with a September 30 fiscal year-end. It was signed May 11, 2012. The filing’s table of contents instead refers to a quarter ended December 31, 2011, and parts of MD&A contain period inconsistencies; the financial statements show the three months ended March 31, 2012.
Business context and financial results
Trail One planned to sell customized decorative automobile license-plate tags. It had not begun major operations or generated revenue and identified itself as a development-stage company.
- Revenue: $0 for both the three and six months ended March 31, 2012.
- Three-month results: Operating expenses were $6,699, including $6,573 in professional fees. Interest expense was $511 and net loss was $7,210. Basic and diluted loss per share were each reported as $0.00.
- Six-month results: Operating expenses were $8,895, including $8,703 in professional fees. Interest expense was $883 and net loss was $9,778. Basic and diluted loss per share were each reported as $0.00.
- Cash flow: Net cash used in operating activities was $8,895 for the six months. Financing provided $8,700, all from additional officer loans; cash decreased $195 to $17. No investing cash flow or interest payments were reported.
- Liquidity and liabilities at March 31: Cash and total assets were $17; current liabilities were $33,636, including $27,193 of related-party notes payable and $1,587 of accrued related-party interest. Working capital and stockholders’ equity were both negative $33,619. Accumulated deficit was $51,619.
- Margins and other metrics: Not meaningful given no revenue. The filing provides no clear debt-maturity schedule beyond the related-party notes being due on demand.
Changes versus comparable periods
For the six months ended March 31, 2012, net loss narrowed to $9,778 from $16,268 in the prior-year period, while operating expenses fell to $8,895 from $16,101. For the three months, net loss was $7,210 versus $7,260 and operating expenses were $6,699 versus $7,106. Revenue remained zero. Compared with September 30, 2011, cash fell from $212 to $17, the related-party note balance rose from $18,493 to $27,193, and the working-capital deficit widened from $23,841 to $33,619.
Outlook, risks, and notable disclosures
- Management said additional capital was necessary to fund operations and pursue the business plan. It estimated a need to raise $75,000 to complete the marketing program and stated that existing liquidity was insufficient for at least the next 12 months. The filing gives a monthly burn-rate estimate of approximately $1,630.
- The company planned an online sales site for September 2012, contingent on obtaining funding, and described a target retail price of approximately $150 per tag. These were plans and estimates, not achieved results or committed orders.
- The filing states that accumulated losses, no revenue, a $33,619 working-capital deficit, and only $17 cash raise substantial doubt about the company’s ability to continue as a going concern. Management was seeking additional capital, with no assurance it would be available.
- The founder and CEO had provided unsecured loans at 8% interest, due on demand. The filing says the company depended on equity and debt financing and warns of possible dilution, restrictive debt terms, or cessation of operations if funding cannot be obtained.
- Disclosure controls and procedures were reported ineffective. The company cited lack of an independent board or audit committee, inadequate segregation of duties, and reliance on a financial consultant for financial reporting.
- Management reported no material legal proceedings, no material change in risk factors, and no material off-balance-sheet arrangements. It stated that no subsequent events required disclosure.
Key facts for investors to verify
- Confirm the issuer: this filing identifies Trail One, Inc., not Citius Pharmaceuticals, Inc.
- Verify the reporting period and quarter: the statements show March 31, 2012, while the table of contents and MD&A include conflicting period references.
- Assess the going-concern risk against the company’s $17 cash balance, $33,636 current liabilities, and stated financing needs.
- Verify whether the planned $75,000 financing, website launch, product pricing, and sales plans were subsequently achieved.
- Review the related-party loans, demand terms, and ineffective disclosure controls.